CHMP5 and COVID-19: Additionally, samples from 11 CLL patients who had received two doses of the BNT162b2 mRNA COVID-19 vaccine were examined; some of these patients had also recovered from recent SARS-CoV-2 infection and tested positive for anti-Spike antibodies.